Biofrontera announced the launch of its FDA-approved RhodoLED XL, a red light emitting LED lamp. This device represents a significant advancement in the treatment of PDT with state-of-the-art engineering, robust but sleek construction and an intuitive user interface. It is designed to be simple to maneuver and able to accommodate various patient treatment positions in order to optimize ease of use. Biofrontera’s PDT drug, Ameluz, is approved by the FDA in combination with either member of the RhodoLED lamp family. The introduction of the RhodoLED XL provides the option to illuminate a larger area in a single on-label Ameluz PDT treatment.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BFRI:
- Biofrontera Announces the Launch of a New, FDA-Approved Red Light Source, the RhodoLED® XL Lamp
- Biofrontera Stockholders Approve Key Governance Decisions
- BFRI Earnings this Week: How Will it Perform?
- Biofrontera Milestones Extend Warrants and Boost Investor Confidence
- Biofrontera Inc. achieves two milestones associated with Series B-3 warrants